Feb. 27—Two Southern Oregon residents are suing CSL Plasma for millions of dollars, saying that their blood plasma donations in Medford caused them stints in the hospital lasting months and ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...

CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production, the latest pharma company to pour money into the country amid tariff threats.

Plasma collection company CSL Plasma and its parent company CSL Behring have settled with the Illinois attorney general's office, resolving a lawsuit alleging the company’s policies discriminate ...

CSL Behring has made a name for itself manufacturing biologics and plasma, but its unveiling of a new R&D site—slated to be the company’s largest—is evidence of expanded development efforts. The new ...

CSL shares are currently trading near a 7-year low. CSL shares have been under pressure, trading near $180, due to softer profits, rising costs, and slow plasma business recovery. Despite recent ...